x

Posted 10 January, 2022

Poseida Therapeutics, Inc. appointed Mark Gergen as new CEO

Nasdaq:PSTX appointed new Chief Executive Officer Mark Gergen in a 8-K filed on 10 January, 2022.


  On January 8, 2022, the board of directors (the "Board") of Poseida Therapeutics, Inc. (the "Company") appointed Mark Gergen as Chief Executive Officer of the Company, effective as of February 1, 2022 (the "Effective Date").  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Poseida Therapeutics, Inc.
Health Care/Life Sciences • Pharmaceuticals
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.
Market Cap
$352M
View Company Details
Poseida Therapeutics, Inc. by TradingView
Relevant filing section
Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


On January 8, 2022, the board of directors (the "Board") of Poseida Therapeutics, Inc. (the "Company") appointed Mark Gergen as Chief Executive Officer of the Company, effective as of February 1, 2022 (the "Effective Date"). Mr. Gergen currently serves as President, Chief Business Officer and a director on the Board. Also as of the Effective Date, Eric Ostertag, M.D., Ph.D., the Company's current Chief Executive Officer, will no longer serve in such role and will assume the role of Executive Chairman of the Board, continuing as a non-executive employee of the Company. 

Prior to the Effective Date, the Company expects to enter into amended employment agreements and related benefits and compensatory arrangements with each of Mr. Gergen and Dr. Ostertag. The current employment agreements and benefits and compensatory arrangements with each of Mr. Gergen and Dr. Ostertag, as well as their biographical information, are described in, and/or filed as exhibits to, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the Securities and Exchange Commission (the "SEC") on March 11, 2021 and the Company's definitive proxy statement on Schedule 14A filed with the SEC on April 28, 2021.